
• Reported GAAP EPS of $0.06 down -33.33% YoY • Reported revenue of $1.58B
Bullish
Avantor exceeded Q1 expectations with improved execution in Bioscience and Medtech Products, which saw a 1.2% net sales increase, and management noted stabilization in VWR.
Bearish
Avantor faced a 4.1% organic net sales decline in Q1 2026, leading to a decrease in net income to $43.3 million and adjusted EBITDA to $219.4 million, reflecting broad margin compression.